We have a long history of supporting a large array of clinical situations as a leading contrast media manufacturer.
Gadopiclenol is an investigational macrocyclic gadolinium-based contrast agent designed and developed by Guerbet’s R&D team. The efficacy and safety of Gadopiclenol have been evaluated as part of the company’s clinical development plan with a view to obtaining worldwide marketing authorization. No regulatory authority has evaluated the clinical study data for this product to date. Details on Phase III clinical trials are available on the ClinicalTrials.gov database.
The information presented is not intended to convey conclusions of safety or efficacy. There is no guarantee that the outcome of these studies will result in approval by health authority.
We look forward to sharing more information about these developments with you in the near future.